help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Cutsem, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Cutsem, E.
The Oncologist, Vol. 9, Suppl 2, 9–15, June 2, 2004
© 2004 AlphaMed Press

The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes

Eric Van Cutsem

University Hospital Gasthuisberg, Leuven, Belgium

Correspondence: Eric Van Cutsem, M.D., Ph.D., University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Telephone: 32-16-344-225; Fax: 32-16-344-419; e-mail: eric.vancutsem{at}uz.kuleuven.ac.be

Globally, gastric cancer is one of the most common types of cancer and one of the most frequent causes of cancer-related death. Despite many advances in the diagnosis and treatment of this disease, the prognosis for gastric cancer remains poor, especially in more advanced stages. In metastatic disease, benefits in survival and quality of life have been demonstrated in patients with unresectable or metastatic gastric cancer receiving chemotherapy plus best supportive care versus best supportive care alone. The taxanes, which are among the most promising cytotoxic agents in clinical use, have shown encouraging activity in early-phase studies as single agents and in combination regimens in the treatment of advanced gastric cancer. Recently, interim results of a randomized phase III trial comparing the triplet of docetaxel, cisplatin, and 5-fluorouracil with a standard reference regimen of cisplatin and 5-fluorouracil were reported. Patients treated with the docetaxel-containing regimen had a statistically superior response rate and time to disease progression as well as a clinically significant prolongation of survival. This study underscores the importance of developing new therapeutic options for patients with advanced gastric cancer.

Key Words. Taxanes • Docetaxel • Paclitaxel • Gastric cancer • Advanced gastric cancer




This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
J.-C. Jo, J.-L. Lee, M.-H. Ryu, S. J. Sym, S. S. Lee, H. M. Chang, T. W. Kim, J. S. Lee, and Y.-K. Kang
Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis
Jpn. J. Clin. Oncol., December 1, 2007; 37(12): 936 - 941.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. A. Ajani
Evolving Chemotherapy for Advanced Gastric Cancer
Oncologist, October 1, 2005; 10(suppl_3): 49 - 58.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
L. Di Lauro, F. Belli, M. G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, and M. Lopez
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer
Ann. Onc., September 1, 2005; 16(9): 1498 - 1502.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.